Combined Vaginal and Vesicoscopic Collaborative Repair of Complex Vesicovaginal Fistulae - 26/09/14
Abstract |
Introduction |
This study aimed to describe and demonstrate the feasibility of a minimally invasive surgical technique for the repair of complex vesicovaginal fistulae that may not be amenable to vaginal repair.
Technical Considerations |
Nine cases of vesicovaginal fistulae, which were repaired laparoscopically at King's College Hospital, London and Ygia Polyclinic Private Hospital, Limassol between 2011 and 2013, were identified. The repair was carried out by direct placement of the ports into the urinary bladder (vesicoscopy). Preoperative, intraoperative, and postoperative data were collected from a prospective database. All 9 operations were completed without any conversion to open surgery. Four ureteric reimplantations were necessary for ureteric involvement. There were no intraoperative complications but some intraoperative technical difficulties. No early postoperative complications were documented, and the hospital stay varied from 2 to 8 days. The fistula repair success rate was 89% at a median follow-up of 30 months.
Conclusion |
This surgical technique is feasible and offers an alternative approach to the classical open or laparoscopic transperitoneal approach. It supplements the vaginal approach for fistulae that are not suitable for pure vaginal approach, allowing close collaboration between the laparoscopic urologist and the vaginal surgeon.
Le texte complet de cet article est disponible en PDF.Plan
Financial Disclosure: Dudley Robinson received funding from Astellas Pharma, Pfizer, Allergan, Ferring, and SEP. Phillipe Grange received funding for research, lecturing, and/or advice or consultancies from Johnson & Johnson and Prosurgics. Linda Cardozo received funding for research, lecturing, and/or advice or consultancies from Astellas Pharma, AMS, Pfizer, and Allergan. She is a member of Global Advisory Board for Solifenancin, co-chairman of the European overactive bladder forum, principal investigator for the SUNRISE study, and speaker at satellite symposia for Astellas Pharma. She is also a member of the Global Advisory Board for Fesoterodine and participant in a multicentre research study. The other authors report no relevant financial interests. |
Vol 84 - N° 4
P. 950-954 - octobre 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?